Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.75 |
| ▸ | DRD3 | P35462 | 14/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20840923 | 1.00 | DRD2 (0.75) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL19629586 | 0.92 | DRD2 (0.76) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL17712724 | 0.86 | DRD2 (1.00) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL17725368 | 0.86 | DRD2 (1.00) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL17725367 | 0.86 | DRD2 (1.00) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL17713011 | 0.86 | DRD2 (1.00) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL17725365 | 0.86 | DRD2 (1.00) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL17725348 | 0.86 | DRD2 (1.00) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| Hydrochloric Acid SCHEMBL19612708 | 0.85 | DRD2 (0.98) | DRD2DRD3KCNH2CYP2D6CHRM1 | |
| SCHEMBL21419051 | 0.84 | DRD2 (0.77) | DRD2DRD3KCNH2CYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | DRD2 2/4885DRD3 1/4885KCNH2 1283/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | DRD2 2/4885DRD3 1/4885KCNH2 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.